Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults.
FDA approves Genentech’s TNKase® in acute ischemic stroke in adults
- Post author:admin
- Post published:March 4, 2025
- Post category:uncategorized